ORIC Pharmaceuticals ORIC
$ 8.17
6.24%
Quarterly report 2024-Q3
added 11-12-2024
ORIC Pharmaceuticals Balance Sheet 2011-2024 | ORIC
Annual Balance Sheet ORIC Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-13.2 M | -54.7 M | -214 M | -78.4 M | -89.2 M | -42.6 M | - | - | - | - | - | - | - |
Long Term Debt |
7.46 M | 9.44 M | 10.5 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.75 M | 2.66 M | 1.93 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 765 K | 109 M | - | - | - | - | - | - | - |
Total Current Liabilities |
20.5 M | 15.4 M | 15.2 M | 9 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
27.9 M | 24.8 M | 25.7 M | 9.22 M | 6.12 M | 111 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-435 M | -334 M | -245 M | - | -92.7 M | -65.8 M | - | - | - | - | - | - | - |
Total Assets |
252 M | 247 M | 299 M | 299 M | 94.1 M | 46.7 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
23.4 M | 66.8 M | 226 M | 78.4 M | 89.2 M | 42.6 M | - | - | - | - | - | - | - |
Book Value |
224 M | 222 M | 273 M | 290 M | 88 M | -64.4 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
224 M | 222 M | 273 M | 290 M | -90.1 M | -64.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet ORIC Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | 10.5 M | 10.7 M | - | 600 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.1 M | 26.5 M | 22.1 M | 27.9 M | 26.9 M | 23 M | 23.8 M | 24.8 M | 23.2 M | 22.8 M | 22 M | 25.7 M | 22.6 M | 9.9 M | 7.88 M | 9.22 M | 9.22 M | 9.22 M | 9.22 M | 6.12 M | 6.12 M | 6.12 M | 6.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-526 M | -492 M | -460 M | -435 M | -407 M | -381 M | -358 M | -334 M | -313 M | -289 M | -268 M | -245 M | -222 M | -204 M | -183 M | -166 M | -166 M | -166 M | -166 M | -92.7 M | -92.7 M | -92.7 M | -92.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
302 M | 329 M | 351 M | 252 M | 274 M | 292 M | 227 M | 247 M | 238 M | 260 M | 275 M | 299 M | 314 M | 268 M | 284 M | 299 M | 299 M | 299 M | 299 M | 94.1 M | 94.1 M | 94.1 M | 94.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
44.2 M | 49.8 M | 56.4 M | 23.4 M | 26.2 M | 104 M | 59 M | 66.8 M | 29.1 M | 49.1 M | 113 M | 226 M | 241 M | 170 M | 104 M | 78.4 M | 78.4 M | 78.4 M | 78.4 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | 42.6 M | - | - | - | 25.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
274 M | 302 M | 329 M | 224 M | 247 M | 269 M | 203 M | 222 M | 215 M | 237 M | 253 M | 273 M | 292 M | 258 M | 276 M | 290 M | 290 M | 290 M | 290 M | 88 M | 88 M | 88 M | 88 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
274 M | 302 M | 329 M | 224 M | 247 M | 269 M | 203 M | 222 M | 215 M | 237 M | 253 M | 273 M | 292 M | 258 M | 276 M | 290 M | 290 M | 290 M | 290 M | -90.1 M | -90.1 M | -90.1 M | -90.1 M | -64.4 M | - | - | - | -43.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency